A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell‐Based Cancer Immunotherapy
Advanced Materials · 2024
DOI: 10.1002/adma.202306736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Yumiao Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, and College of Life Sciences, Nankai University, Tianjin, …. Hauptthemen laut MEDLINE: Nanotubes, Carbon, Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for Central Universities of Nankai University, Tianjin Key Medical Discipline (Specialty) Construction Project.
Abstract (Originalsprache)
Immune cells are pivotal in cancer immunotherapy, yet their therapeutic effectiveness is often hampered by limited tumor infiltration and inhibitory tumor microenvironments. An alkaline phosphatase (ALP)‐responsive and transformable supramolecular bis‐specific cell engager (Supra‐BiCE) to harness natural killer (NK)/T cells for effective cancer immunotherapy is introduced here. The Supra‐BiCE, consisting of both SA‐P (a phosphorylated peptide targeting and blocking programmed cell death ligand 1 (PD‐L1)) and SA‐T (a phosphorylated peptide targeting and blocking T cell immunoglobulin and ITIM domain (TIGIT)) is constructed by a simple co‐assembling strategy. Upon intravenous administration, Supra‐BiCE self‐assembles into nanoribbons and interacts with NK/T cells via TIGIT. Notably, these nanoribbons undergo transformation into long nanofibrils within ALP‐overexpressing tumor regions, resulting in enhanced binding affinities of Supra‐BiCE to both PD‐L1 and TIGIT. Consequently, this leads to the accumulation and retention of NK/T cells within tumor regions. Furthermore, the combinatorial blockade of checkpoints by Supra‐BiCE activates infiltrating NK/T cells. Moreover, the adjustable peptide ratio in Supra‐BiCE enables customization for optimal therapeutic effects against distinct tumor types. Particularly, Supra‐BiCE (T:P = 1:3) achieved 98.27% tumor suppression rate against colon carcinoma model. Overall, this study offers a promising tool for engaging NK and T cells for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, and College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, P. R. China.
- Department of Urology, Tianjin First Central Hospital, Tianjin, 300192, China.
ORCID-Profile: Yumiao Chen, Zhimou Yang, Jie Gao
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for Central Universities of Nankai University
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Chen, Y., Li, W., Wang, Z., Yu, Y., Li, J., Ding, Y., Hu, Z., Liu, Q., Yang, Z., & Gao, J. (2024). A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell‐Based Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202306736
Vancouver
Chen Y, Li W, Wang Z, Yu Y, Li J, Ding Y, et al. A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell‐Based Cancer Immunotherapy. Advanced Materials. 2024. doi:10.1002/adma.202306736
BibTeX
@article{Chen2024,
author = {Chen, Yumiao and Li, Wei and Wang, Zhongqiu and Yu, Yingying and Li, Jie and Ding, Yinghao and Hu, Zhiwen and Liu, Qian and Yang, Zhimou and Gao, Jie},
title = {A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell‐Based Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202306736}
}
EUVIMED